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Objectives. This study was designed to determine whether
angiotensin-converting enzyme (ACE) inhibitors play a role in
cardioprotection in a human model of preconditioning.
Background. Recent studies have suggested that bradykinin
may contribute to the protective effects of preconditioning in
animal models. ACE inhibitors are known to inhibit the degrada-
tion of bradykinin and hence may be able to potentiate the effect
of preconditioning.
Methods. We examined the effects of the ACE inhibitors
captopril and lisinopril in combination with a subthreshold
preconditioning stimulus (i.e., insufficient to have any protective
effects alone). Human atrial trabeculae were superfused with
Krebs buffer and paced at 1 Hz. They were subjected to a full or
subthreshold preconditioning stimulus consisting of either 3 or
1.5 min of simulated ischemia and 7 min of reoxygenation. In each
instance, this stimulus was followed by 90 min of simulated
ischemia and 2 h of reoxygenation. In addition, the subthreshold
preconditioned group had 20 min of previous ACE inhibitor
treatment.
Results. Recovery of contractile function (percent of baseline)
was 22 6 1% (mean 6 SEM) in the control group versus 61 6 1%
in the preconditioned group. The subthreshold preconditioned
group and the ACE inhibitor-alone groups did not exhibit any
protection; however, in combination, the protection was signifi-
cant (71 6 4% in the captopril group, 58 6 8% in the lisinopril
group, p < 0.005) compared with the control group. There was no
significant difference between these values and recovery after the
full preconditioning stimulus. Furthermore, Hoe 140, a specific
bradykinin B2 receptor antagonist, abolished the protection.
Conclusions. To our knowledge, these are the first results in
human muscle to suggest that ACE inhibitors may augment
ischemic preconditioning, possibly through B2 receptor activation.
(J Am Coll Cardiol 1997;29:1599–606)
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The introduction of angiotensin-converting enzyme (ACE)
inhibitor therapy has had an enormous impact on clinical
practice, far beyond initial expectations when first introduced
as antihypertensive agents. As well as their use in the manage-
ment of heart failure, they are now being implicated as
myocardial and vascular “protective” agents that not only
prevent left ventricular remodeling, but also reduce myocardial
ischemic events. These anti-ischemic and antiremodeling ef-
fects were somewhat unexpected, and the exact mechanisms
involved are uncertain. Large trials, such as the Studies of Left
Ventricular Dysfunction (SOLVD) (1) and Survival and Ven-
tricular Enlargement (SAVE) (2) trials, have shown a signifi-
cant effect of ACE inhibitors on the prevention of myocardial
ischemic events. More recent evidence comes from trials such
as Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico III (GISSI-3) (3), in which the
lisinopril-treated group had a significant reduction in early
mortality (6 weeks), and Fourth International Study of Infarct
Survival (ISIS-4) (4), which showed a 7% decrease in 5-week
mortality in the captopril group.
There is accumulating evidence for a direct protective role
for ACE inhibitors in the ischemic/reperfused myocardium
(5–9), although the published reports are conflicting. Experi-
ments to date have largely demonstrated this protective effect
if the ACE inhibitor is given as pretreatment before infarction.
It was proposed that ACE inhibitors protect in this manner by
inhibiting the breakdown of bradykinin (9) because Hoe 140
has been shown to reverse the protective effect (6,7). A recent
study by Miki et al. (10), showed that captopril potentiates the
infarct size–limiting effect of ischemic preconditioning through
bradykinin B2 receptors in a rabbit model.
Ischemic preconditioning is another phenomenon that of-
fers the myocardium an extremely powerful means of self-
protection. During ischemia, locally produced mediators, such
as adenosine, catecholamines and bradykinin, may act as
triggers of preconditioning, in which resistance to ischemic
injury is enhanced by previous exposure to a brief episode of
ischemia followed by reperfusion. The importance of these
mediators requires further elucidation, although the involve-
ment of the adenosine receptor in the human heart was
previously confirmed by our group (11). The question remains,
Is there a role for some of the other putative mediators of
preconditioning in the human heart?
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There is now increasing awareness that ACE inhibitor
activity is mediated in part through increased local bradykinin
levels. Intracardiac production of bradykinin has been shown
to be increased in myocardial ischemia (8,12,13), and, further-
more, recent reports suggest that infarct size limitation in the
rabbit is blocked by the B2 receptor antagonist Hoe 140 and
mimicked by kinin administration (7).
It has also been reported that direct intracoronary infusion
of bradykinin can reduce infarct size in dogs (14) and also
mimic preconditioning by reducing the severity of ischemia-
induced arrhythmias (5). These effects have been proposed to
be mediated through prostacyclin or nitric oxide, or both, and
increasing cyclic guanosine monophosphate.
We recently developed a model of preconditioning using
isolated superfused isometrically contracting human atrial
trabeculae. This model has the advantage of avoiding compli-
cations of collateral flow, and the mix of necrotic and viable
tissue within each specimen is comparable to the situation in
evolving acute myocardial infarction. Previous studies have
established that in this model, the protective effects of precon-
ditioning can be induced by activation of adenosine A1 recep-
tors (11) and that protein kinase C (PKC) and the activation of
the ATP-dependent potassium channel (KATP) are also in-
volved (15), confirming results obtained in animal studies.
The aim of the present study was to determine whether
ACE inhibitors, (with and without sulfhydryl groups) could
contribute to the protective effects of preconditioning. Fur-
thermore, using a specific B2 receptor antagonist, Hoe 140, our
aim was to determine whether any protective effect observed is
related to enhanced bradykinin B2 receptor activation after
reduced kinin degradation.
Methods
Experimental model. Experiments were performed in tra-
beculae derived from human atrium. Specimens of right atrial
appendage were obtained from the right atrial cannulation site
in patients undergoing coronary artery bypass grafting (46
patients, 37 men, 9 women; 39 to 79 years old, mean age 64).
All patients had chronic stable angina, and those with right
ventricular failure or atrial arrhythmias or taking antiarrhyth-
mic medication were excluded. Patients taking oral hypoglyce-
mic agents and those receiving ACE inhibitors were also
excluded. Ethical approval for this procedure was obtained
from the hospital ethics committee. The specimens were
transported to the laboratory in oxygenated modified Tyrode’s
solution.
Atrial trabeculae (diameter 0.9 mm, length $ 3 mm) were
dissected under magnification in a dish superfused with Ty-
rode’s solution, tied at one end with a 7/0 silk suture and
removed together with a small portion of atrial wall at the free
end. The silk suture was then used to attach the muscle to a
fixed post in an organ bath while the free end was attached to
a force transducer (Gould Statham UCT 2) using a snare
around the wedge of atrial wall. The muscles were suspended
horizontally in the organ bath through which there was a
continuous flow of superfusate oxygenated with a 95% O2/5%
CO2 gas mixture. The superfusate was a modified Tyrode’s
solution of the following composition (mmol/liter): NaCl 118.5,
KCl 4.8, NaHCO3 24.8, KH2PO4 1.2, MgSO4z7H2O 1.44,
CaCl2z2H2O 1.8, glucose 10.0 and pyruvic acid 10.0. In the
substrate-free Tyrode’s solution, 7 mmol/liter choline chloride
was substituted for glucose and pyruvic acid to maintain
constant osmolarity. All reagents were AnalaR grade from
BDH Chemicals, Poole, England, except for pyruvic acid from
Sigma Chemicals. The organ bath was covered to prevent gas
exchange with the atmosphere. Gas tensions in the organ bath
were analyzed intermittently using an automated blood gas
analyzer (AVL 993, AVL Medical Instruments, Switzerland).
The pH was maintained between 7.35 and 7.45, the partial
pressure of O2 between 50 and 60 kPa and partial pressure of
CO2 between 4.0 and 6.0 kPa. During simulated ischemia, the
superfusate was free of substrate and was bubbled with 95%
N2/5% CO2 to lower the partial pressure O2 in the organ bath
to 6 to 8 kPa. (pH 7.24 to 7.34). The organ bath and preorgan
bath heat exchanger were both water jacketed and circulated
(Techne circulator C 85-A, Cambridge, UK) to maintain a
constant temperature of 37.0 6 0.1°C, which was monitored
through a thermocouple in the bath. The length and width of
the trabecular muscles were recorded at the end of the
experiment using an eyepiece graticule in an overhead micro-
scope (Prior, UK), and all specimens were then weighed. The
cross-sectional area was calculated by dividing muscle mass
by length times density, assuming a cylindric shape and a
density of 1.0 mg/mm3. To ensure that initial comparisons of
developed tensions and rest force were not affected by
variable muscle size, cross-sectional area of the muscles was
used to calculate tensions. In addition, all muscles with a
cross-sectional area .1.2 mm2 were excluded from the study
(16).
Muscle stimulation and recording of data. Once horizon-
tally suspended, trabeculae were paced by field stimulation
at 1 Hz by parallel flattened platinum electrodes with an
isolated stimulator (Digitimer DS2, Hertfordshire, UK)
triggered by a programmable computerized clock. The pulse
width was fixed at 5 ms and the pulse amplitude set at twice
threshold (6 to 8 mV). Contractile force was amplified and
recorded on paper (Universal Amplifier and RS3400 ink pen
recorder, Gould).
Chemicals. Captopril and lisinopril were obtained from
Sigma. Captopril was dissolved in normal saline and added to
Tyrode’s solution to give a final concentration of 10 mmol/liter,
and lisinopril was similarly dissolved to give a final concentra-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
KATP 5 ATP-dependent potassium channel
PKC 5 protein kinase C
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tion of 20 mmol/liter—concentrations comparable to plasma
levels in patients taking these particular ACE inhibitors (17).
Hoe 140 was diluted to a final concentration of 20 nmol/liter,
a concentration known to be sufficient to effectively antagonize
B2 receptors.
Experimental protocols. Trabeculae were initially stimu-
lated at 1 Hz unstretched for 30 min to allow time for recovery.
They were subsequently stretched in a stepwise manner over
15 min to a length developing 90% of maximal force and
allowed to equilibrate for a further 30 min. All groups even-
tually underwent a period of simulated ischemia that consisted
of 90 min of hypoxic substrate-free superfusion and rapid
pacing at 3 Hz, followed by reperfusion for 120 min with
oxygenated Tyrode’s solution and pacing of trabeculae at 1 Hz.
The preconditioning protocol consisted of 3 min of hypoxic
substrate-free superfusion with trabeculae paced at 3 Hz,
followed by 7 min of reperfusion with oxygenated Tyrode’s
solution with substrate and pacing at 1 Hz. A subthreshold
preconditioning protocol was established that failed to protect
alone. This protocol consisted of 90 s of pacing at 3 Hz with
hypoxic substrate-free perfusate and was also followed by
7 min of reperfusion with oxygenated Tyrode’s solution. Figure
1 shows the experimental protocols for the 10 groups, all of
which were finally subjected to 90 min of simulated ischemia:
1) Control protocol 5 stabilization period followed by 90 min of
ischemia; 2) ACE inhibitor protocol 5 superfusion with capto-
pril or lisinopril for 20 min before 90 min of ischemia; 3)
preconditioning protocol 5 preconditioning followed by 90 min
of ischemia; 4) subthreshold preconditioning protocol 5 sub-
threshold preconditioning followed by ischemia; 5) ACE inhib-
itor plus subthreshold preconditioning protocol 5 20 min of
superfusion with captopril or lisinopril, followed by subthresh-
old preconditioning; 6) Hoe 140 plus subthreshold precondition-
ing protocol 5 superfusion with Hoe 140 for 20 min before
subthreshold preconditioning; and 7) Hoe 140 plus ACE inhib-
itor plus subthreshold preconditioning protocol 5 superfusion
with Hoe 140 for 10 min before addition of captopril or
lisinopril for 20 min, followed by subthreshold preconditioning.
For all these groups n 5 6, including six experiments for each
ACE inhibitor, with a maximum of two trabeculae from each
heart.
Statistical analysis. Results are presented as mean value 6
SEM. Statistical differences between groups were evaluated by
two-way analysis of variance followed by a Fisher protected
least significant difference post hoc test with respect to treat-
ment and time; p # 0.05 was considered significant.
Figure 1. Experimental protocols (n 5 6
for all groups). All protocols were pre-
ceded by at least a 45-min stabilization
period (Perf). Hatched areas 5 isch-
emia; isch 5 superfusion with hypoxic
substrate-free Tyrode’s solution and
pacing at 3 Hz; PC 5 preconditioning;
reper 5 reperfusion with oxygenated
Tyrode’s solution and pacing at 1 Hz;
sPC 5 subthreshold preconditioning.
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Results
Exclusions. Three muscles were excluded because of a
calculated cross-sectional area .1.2 mm2. There were no other
exclusions, and all samples completed the protocol to which
they were randomly assigned.
Analysis of data. The physical characteristics of the trabec-
ulae and baseline functional data were similar in all 10 groups
(Table 1), including rest and developed force. Therefore,
experimental data on developed force are presented graphi-
cally as percent of baseline developed force.
The addition of an ACE inhibitor at the beginning of the
experiment led to a minor, but nonsignificant, reduction in
developed force. The 3-min or 90-s preconditioning protocols
resulted in a significant reduction in developed force that
recovered to baseline on reperfusion before the long ischemic
insult.
Figures 2 to 5 show the results for developed force as a
percent of baseline. Time 0 indicates the beginning of simu-
lated ischemia; therefore, reperfusion with oxygenated Ty-
rode’s solution extends from 90 to 210 min. As indicated in the
diagram of the protocols (Fig. 1), simulated ischemia is
preceded in all groups by a stabilization period and various
pretreatments (indicated on the graphs by an arrow). As noted,
there was no significant difference in developed force between
the 10 groups at the end of the stabilization period, and this
baseline function is denoted as 100% developed force.
Figure 2 illustrates the synergistic effect of pretreatment
with an ACE inhibitor in combination with a subthreshold
preconditioning stimulus. The level of protection observed is
of a similar magnitude to that obtained with the standard
3-min ischemic preconditioning protocol, although captopril
was significantly more protective than lisinopril at the last two
time points. Recovery was 22 6 1% in the control group
compared with 61 6 1% in the preconditioned group, 71 6 4%
in the captopril plus subthreshold preconditioned group and
58 6 8% in the lisinopril plus subthreshold preconditioned
group (at the end of reperfusion, i.e., 210 min). There was no
protection in the group receiving subthreshold ischemic pre-
conditioning alone (23 6 4%); this group had a level of
recovery similar to that of the control group (no pretreatment).
ACE inhibitor pretreatment alone had no protective effects
in contrast to the marked protection observed when combined
with subthreshold preconditioning, as seen in Figure 3. In
addition, Hoe 140 pretreatment alone did not adversely affect
recovery compared with that in the control group, with a
maximal recovery in this group of 20 6 5%.
Figures 4 and 5 illustrate the effects of pretreatment with
the B2 receptor antagonist Hoe 140 on the captopril- and
Table 1. Physical Characteristics and Baseline Functional Data of Trabeculae Study Groups
Group
Length
(mm)
Mass
(g)
Diameter
(mm)
Rest
Force
(g)
Developed
Force
(g)
Control 4.4 6 0.3 0.006 6 0.001 0.71 6 0.04 0.65 6 0.11 1.20 6 0.16
Cap 4.5 6 0.3 0.006 6 0.001 0.73 6 0.04 0.77 6 0.10 1.51 6 0.18
Lis 4.9 6 0.5 0.005 6 0.001 0.77 6 0.06 0.70 6 0.09 1.43 6 0.13
PC 4.2 6 0.3 0.005 6 0.001 0.71 6 0.05 0.71 6 0.10 1.38 6 0.19
sPC 4.5 6 0.4 0.005 6 0.001 0.69 6 0.05 0.78 6 0.10 1.35 6 0.20
Cap1sPC 5.0 6 0.4 0.006 6 0.001 0.71 6 0.05 0.77 6 0.11 1.26 6 0.21
Lis1sPC 4.7 6 0.3 0.006 6 0.001 0.79 6 0.02 0.66 6 0.11 1.19 6 0.21
Hoe1sPC 4.6 6 0.4 0.005 6 0.001 0.69 6 0.05 0.68 6 0.12 1.28 6 0.17
Hoe1Cap1sPC 4.5 6 0.3 0.006 6 0.001 0.68 6 0.06 0.75 6 0.12 1.47 6 0.22
Hoe1Lis1sPC 4.7 6 0.4 0.006 6 0.001 0.71 6 0.05 0.67 6 0.13 1.48 6 0.19
Data presented are mean value 6 SEM. Cap 5 captopril; Hoe 5 Hoe 140; Lis 5 lisinopril; PC 5 preconditioning;
sPC 5 subthreshold preconditioning.
Figure 2. Developed force expressed as percent of baseline force over
time (min), illustrating that the combination of an ACE inhibitor with
subthreshold preconditioning (sPC) results in a similar degree of
recovery in the group receiving the full preconditioning protocol (PC
[solid squares]). Recovery of the subthreshold preconditioning-alone
group (open squares) is not statistically significant from control group
(solid circles). Solid triangles 5 captopril plus subthreshold precon-
ditioning; open circles 5 lisinopril plus subthreshold preconditioning.
*p , 0.005 versus control and subthreshold preconditioning.
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lisinopril-treated groups, respectively. In Figure 4 it can be
seen that Hoe 140 clearly abrogates the protective effects of
captopril in combination with subthreshold preconditioning,
with a functional recovery of 35 6 5%. However, there is some
residual protective effect observed, although this was not
significant. Figure 5 also shows that Hoe 140 abrogates the
protective effects of lisinopril in combination with subthreshold
ischemic preconditioning (31 6 5%).
Discussion
Study findings. This study shows that ACE inhibition in
combination with a subthreshold preconditioning stimulus
resulted in a significant degree of protection, in terms of
recovery of function, when the trabeculae were subjected to a
subsequent 90-min period of simulated ischemia. The degree
of protection provided by combined subthreshold precondi-
tioning and ACE inhibition is of a comparable degree to that
after a full ischemic preconditioning protocol. Furthermore,
the cardioprotective effect was abolished by pretreatment with
the B2 receptor antagonist Hoe 140. These results support the
hypothesis that generation of bradykinin during precondition-
ing contributes, through B2 receptor activation, to the protec-
tion observed in terms of improved postischemic functional
recovery. However, pretreatment with ACE inhibitor alone did
not result in protection, perhaps because a degree of ischemia
is required to release bradykinin initially, or other mediators,
such as adenosine, are required in addition to trigger precon-
ditioning.
There are several clinical studies suggesting that precondi-
tioning occurs in humans (18–20), with evidence from in vitro
studies using isolated human ventricular cardiomyocytes that
were protected against a 90-min period of simulated ischemia
by a preconditioning protocol (21). The other studies are from
our own group (11,15) using the same model as that in the
present study. These studies have demonstrated that precon-
ditioning of human atrial trabeculae results in a significantly
better postischemic recovery of contractile function than non-
preconditioned trabeculae and, in common with animal mod-
els of preconditioning, have confirmed a role for adenosine
receptors and PKC (11,15).
Human atrial model. The present study used isolated
human atrial trabeculae to examine the mechanism of precon-
ditioning in human myocardium. Atrial specimens make stable
preparations, and sampling was part of the routine procedure
for coronary artery bypass graft surgery. However, there are
differences between atrial and ventricular tissue, and the
results from one may not be applicable to the other.
The present study used a period of hypoxic superfusion in
combination with rapid pacing to simulate ischemia rather
than the “true” ischemia of ischemic preconditioning. How-
ever, there is a great deal of evidence (22–25) in animal models
of both regional and global hypoxia and in cell cultures that
hypoxia is as effective as ischemia in inducing preconditioning.
We know that preconditioning attenuates contractile dysfunc-
tion as well as reducing infarct size. For example, Jenkins et al.
(26), who measured both infarct volume and functional recov-
ery after ischemia, showed that the improved recovery of
Figure 3. Developed force expressed as percent of baseline force over
time (min), comparing the combination of ACE inhibitor plus sub-
threshold preconditioning (sPC) with ACE inhibitor alone. The per-
cent of recovery in the ACE inhibitor plus subthreshold precondition-
ing groups is significantly greater than that in the ACE inhibitor-alone
groups (*p , 0.005). Open circles 5 lisinopril; solid circles 5 lisinopril
plus subthreshold preconditioning; solid squares 5 captopril; open
squares 5 captopril plus subthreshold preconditioning.
Figure 4. Developed force expressed as percent of baseline force over
time (min), illustrating that pretreatment with Hoe 140 abrogates the
protective effect of captopril in combination with subthreshold pre-
conditioning (sPC) (solid circles) (*p , 0.005). Recovery of the
Hoe 140-pretreated group was not statistically significant from that for
the control group. Solid squares 5 Hoe 140 plus captopril plus
subthreshold preconditioning; open squares 5 subthreshold precondi-
tioning; PC 5 preconditioning.
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global left ventricular function produced by preconditioning is
proportional to a reduction in infarction, and Cohen et al. (27)
and Przyklenk et al. (28) were able to correlate improved
recovery of systolic shortening with reduced infarct size in
in vivo models of regional ischemia. Clearly, these studies
demonstrate that the enhanced recovery of contractile function
due to preconditioning that follows a prolonged period of
ischemia results from a reduction in infarct size and is not due
to a reduction in stunning. Our model used a 90-min period of
simulated ischemia as the ischemic insult, a period more likely
to result in cell death than stunning, which is induced by
shorter periods of 5 to 15 min of ischemia. Hence, there is
evidence that hypoxia can be as effective as ischemia in
preconditioning, that recovery of contractile function is a good
correlate for the degree of myocardial necrosis and that this
experimental model is representative of the preconditioning
phenomenon.
Role of bradykinin. Although we did not measure kinin
levels in our samples, Hoe 140 is the most specific and potent
B2 receptor antagonist currently known. It has virtually the
same affinity for B2 receptors as bradykinin itself and does not
react with receptors for other peptides. Furthermore, kinin
release from ischemic myocardium has been well documented
in the isolated rat heart in vitro (13,29) and the canine
myocardium in vivo (30,31). Baumgarten et al. (13) showed
that kinin release after 15 min of coronary occlusion was
enhanced by pretreatment with an ACE inhibitor, ramiprilat,
in isolated rat hearts. Furthermore, Nolly et al. (32) demon-
strated that the heart contains an independent kallikrein–kinin
system. They demonstrated the presence of kallikrein (a potent
kinin-generating enzyme) mRNA in rat atria and ventricles
and kallikrein activity in primary cultures of neonatal rat atrial
and ventricular cardiocytes and in their incubation medium.
Heart slices were shown to release kallikrein without depletion
of total tissue kallikrein, suggesting pool replenishment. In
fact, kininogen was found in epicardial slices and in the Krebs
solution bathing the slices (which were washed and reincu-
bated in Krebs solution)—and this release was inhibited by
pretreatment with puromycin—suggesting primary synthesis.
Presumably, ischemia results in pH and other changes that
cause activation of kallikrein within the myocardium and the
subsequent local availability of bradykinin (33). Hence, this
work supports the hypothesis that local production of kinin
contributed to the protection observed.
Relevance of the sulfhydryl moiety. Protection was ob-
served for both a sulfhydryl-containing ACE inhibitor, capto-
pril, and a non–sulfhydryl-containing one, lisinopril. However,
for the last two time points, recovery in the captopril group was
significantly greater than that in the lisinopril group, although
both ACE inhibitors in combination with subthreshold precon-
ditioning provided significant protection from 150 min of
reperfusion onward. The greater beneficial effect of captopril
over lisinopril could theoretically be due to the free radical
scavenging ability conferred by the presence of the OSH
moiety. Another mechanism by which ACE inhibitors may
provide protection is through activation of the KATP channel.
Sargent et al. (34) found that the sulfhydryl-containing ACE
inhibitor zofenopril induced cardioprotection through modu-
lation of the KATP channel. Indeed, the cardioprotection
observed in ischemic rat hearts with zofenopril was abolished
by the KATP blockers glyburide and 5-hydroxydecanoate.
Our results show that ACE inhibition alone is insufficient to
confer any protection after 90 min of ischemia. This result is
consistent with previously published studies (35–38). However,
the situation is not clear-cut, and there are some reports of
infarct size limitation by the same agents (6,39). Our results are
compatible with a current concept of preconditioning as a
phenomenon that may have several different endogenous
mediators, such as adenosine and bradykinin, that stimulate
PKC to a certain threshold sufficient to trigger the intracellular
pathways necessary for providing protection against a further
ischemic insult (33). Recently, Goto et al. (33) found that
Hoe 140 blocked the protection from one 5-min period of
preconditioning but could not block protection when a more
profound preconditioning stimulus was used in a rabbit model.
Hence, it is possible that the adenosine and bradykinin re-
leased during the subthreshold ischemia is insufficient to
trigger protection unless the level of bradykinin is augmented
by ACE inhibition, as illustrated in Figure 6.
It is possible that the interaction between adenosine and
bradykinin may not simply be additive, but a study (40) in
smooth muscle cells found that stimulation of adenosine A1
and bradykinin receptors results in a synergistic increase in
inositol 1,4,5,-triphosphate and free calcium levels.
Intracellular signaling pathways. The present study does
not address the issue of the cardioprotective mechanism
Figure 5. Developed force expressed as percent of baseline force over
time (min), illustrating that pretreatment with Hoe 140 abrogates the
protective effect of lisinopril in combination with subthreshold precon-
ditioning (sPC) (solid circles) (*p , 0.005). Solid squares 5 Hoe 140
plus lisinopril plus subthreshold preconditioning; open squares 5
subthreshold preconditioning; PC 5 preconditioning.
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downstream to activation of the B2 receptor. This receptor is
coupled to phospholipases A2 and C through G proteins
(41,42), and stimulation of this receptor leads to the produc-
tion of two important vasoactive substances—prostacyclin and
nitric oxide. However, neither cyclooxygenase inhibitors (43)
nor the nitric oxide synthase inhibitor nitro-L-arginine methyl
ester (12,44) attenuated infarct size limitation by precondition-
ing in a rabbit model of infarction. In contrast Goto et al. (12)
demonstrated that polymyxin B, a blocker of PKC, abolished
infarct size limitation by treatment with a kinin. Furthermore,
it was recently observed (45) that B2 receptor stimulation
caused significant inositol triphosphate production in isolated
cardiac myocytes, suggesting that simultaneously generated
diacylglycerol could activate PKC. Hence, these observations
suggest that PKC activation plays a role in bradykinin-
mediated protection.
Role of angiotensin II. The present study does not take
into account the simultaneous suppression of angiotensin II
production, which has been reported in some recent studies
(46) to contribute to ischemic preconditioning; and angioten-
sin II receptor activation can mimic preconditioning (47).
Hence, the effect of ACE inhibition in the reduction of
angiotensin II levels would tend to lead to an underestimation
of the protective effect observed with respect to bradykinin
because some of the angiotensin II–mediated component
could theoretically be reduced. In terms of implications for
future therapy, development of a specific kininase inhibitor
without the ACE inhibitory component could be valuable in
this setting. Furthermore, agents such as angiotensin II recep-
tor antagonists would not have this bradykinin-potentiating
effect.
Conclusions. We demonstrated in a human model that
ACE inhibitors can potentiate the effects of a subthreshold
preconditioning stimulus and that B2 bradykinin receptors may
play a role in this protection. To our knowledge, this is the first
report to allude to a potential role for bradykinin as a mediator
in human preconditioning, giving a possible clue to the mech-
anisms involved in the reduction of fatal ischemic events in
patients treated with ACE inhibitors observed in the multi-
center trials.
We thank R. N. Zahlten and B. A. Scholkens, Hoechst, Frankfurt, Germany for
the Hoe 140.
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